

Viral Vectors & Vaccines

Process Development and Production Issues

November 10 – 13, 2003

Sunday, November 9

4:00–6:00 pm: *Registration, Welcome Reception, and Exhibit Setup*

Monday, November 10

7:00–8:00 am: *Registration and Continental Breakfast — Meeting Room Foyer*

8:00–8:30 am: **Introduction**

Keith L. Carson — *Conference Chairman*

8:30–9:15 am: **Assessment of Stability for Adenoviral Vectors**

Bryan Butman, Ph.D. — *GenVec, Inc.*

9:15–10:00 am: **Development of a Potency Assay for a Selectively Replicating, Oncolytic Adenovirus Vector**

Thomas Schluep — *Canji, Inc.*

10:00–10:30 am: **Break—Exhibit Area**

10:30–11:15 am: **Large-Scale Purification of a Lentiviral Vector by Size Exclusion Chromatography or Ion Exchange Capsule**

Vladimir Slepishkin, Ph.D.—*VIRxSYS Corporation*

11:15–12:00 noon: **Scalable Processes for rAAV Manufacturing**

Barb Thorne, Ph.D.—*Targeted Genetics Corporation*

12:00–1:30 pm: *Carnival de Bellagio Lunch—Exhibit Area*

1:30–2:15 pm: **Determination of Particle Heterogeneity of Recombinant Adenovirus by Analytical Ultracentrifugation in CsCl Gradients**

Xiao Yu Yang — *Schering-Plough Corporation*

2:15–3:00 pm: **Safety and Efficacy of Rexin-G, the World's First Targeted Injectable Vector as Treatment for Advanced Pancreatic Cancer**

Erlinda Gordon, M.D.—*Epeius Biotechnologies Corp.*

3:00–3:30 pm: **Break — Exhibit Area**

3:30–4:15 pm: **An Assessment of the Normalized-Adjusted Standard [NAS] Method Used to Calculate Infectious Titer of Adenoviral Preparations**

Barry Sugarman, Ph.D. — *Canji, Inc.*

4:15–5:00 pm: **AAV-based Vectors for Hemophilia and Parkinson's Disease: Development Challenges**

Fraser Wright, Ph.D. — *Avigen, Inc.*

6:00–7:30 pm: *“What Happens in Vegas, Stays in Vegas” Reception — Exhibit Area*

Tuesday, November 11

7:30–8:30 am: *American Breakfast — Exhibit Area*

8:30–9:15 am: **Thermal and Genetic Stabilities of Vaccinia Virus Vectors**

Elisabeth Keppi — *Transgene S.A.*

9:15–10:00 am: **Process Development and cGMP Production of Viral Vectors for a Phase I Clinical Trial in a BSL-3 Laboratory**

Jinhua Lu, Ph.D. — *SAIC Frederick*

10:00–10:30 am: **Break — Exhibit Area**

10:30–11:15 am: **Of Ancillary Products, Sterility, Bioassays, etc.: An Update of Happenings at the USP**

Sally Seaver, Ph.D. — *Seaver Associates*

11:15–12:00 noon: **Identification of Pretreatment Agents to Enhance the Adenovirus Infection of Uro-epithelium**

Eric Memarzadeh, Ph.D. — *Cell Genesys, Inc.*

12:00–6:00 pm: **Free Afternoon with Recommended Group Activities**

6:00–9:00 pm: **“Viva Las Vegas” Conference Banquet — Bellagio, Monet Room and Terrace**

Wednesday, November 12

7:30–8:30 am: **Continental Breakfast — Exhibit Area**

8:30–10:00 am: **Technical Workshops I**

10:00–10:30 am: **Break — Exhibit Area**

10:30–12:00 noon: **Technical Workshops II**

12:00–1:30 pm: **Deli Luncheon Buffet — Exhibit Area**

1:30–2:15 pm: **Production and Safety Testing of EIAV-Based Lentiviral Vectors**
David Driver — *BioMedica, Inc.*

2:15–3:00 pm: **Development of a Cell Culture-Derived Smallpox Vaccine**
Florence Wu, Ph.D. — *BioReliance Corporation*

3:00–3:30 pm: **Break — Exhibit Area (Exhibit Teardown at 3:30 pm)**

3:30–4:15 pm: **Defining a Detailed Approach to Using the Adenovirus Reference Material (ARM)**
Nancy Sajjadi — *Sajjadi Associates, Inc.*

4:15–5:00 pm: **Improved Adenoviral-Based Vaccines to Circumvent Ad5 Preexisting Immunity**
Maria Grazia Pau — *Crucell B.V.*

5:30–6:30 pm: **Bellagio Happy Hour — Exhibit Area**

Thursday, November 13

7:30–8:30 am: **Continental Breakfast — Meeting Foyer**

8:30–9:15 am: **Assessment of Aggregation Phenomena in Preparations of Recombinant Viruses by DLS**
Maria Croyle, Ph.D. — *The University of Texas at Austin, College of Pharmacy*

9:15–10:00 am: **Lentivirus Reference Material Update**
Veronique Kiermer, Ph.D. — *Cell Genesys, Inc.*

10:00–10:30 am: **Break — Meeting Foyer**

10:30–11:15 am: **PEGylation of Virus: Application of Fluorescence-Labeled PEG**
Seoju Lee, Ph.D. — *Schering-Plough Corporation*

11:15–12:00 noon: **FGF-4 Potency Assays for the Ad5FGF-4 Gene Therapy Product**
Farah Fawaz, Ph.D. — *Berlex BioSciences*

12:00–12:45 pm: **Viral Clearance: What Can You Do When Your Product Itself Is a Live Virus?**
Kenneth Hughes, Ph.D. — *Microbix Biosystems, Inc.*

Due to circumstances beyond the control of the conference organizers, the speaker list is subject to change.

Participating Exhibitors Include:

- | | | | |
|--------------------------------|------------------------------|--|--------------------------------|
| ◆ Alfa Wassermann | ◆ Cobra | ◆ JRH Biosciences | ◆ Puresyn, Inc. |
| ◆ Althea Technologies, Inc. | ◆ Corning, Inc. | ◆ Kendro Laboratories | ◆ Qbiogene, Inc. |
| ◆ Amersham Biosciences | ◆ Crucell N.V. | ◆ Microbix Biosystems Inc. | ◆ Q-One Biotech Inc. |
| ◆ Applikon Biotechnology, Inc. | ◆ CUNO Inc. | ◆ Millipore Corp. | ◆ Seqwright, Inc. |
| ◆ AppTec Laboratory Services | ◆ EMD Chemicals, Inc. | ◆ Molecular Medicine Bioservices, Inc. | ◆ Sigma-Aldrich Fine Chemicals |
| ◆ Beckman Coulter, Inc. | ◆ Gibco/Invitrogen Corp. | ◆ Nalge Nunc International | ◆ Spectrum Laboratories, Inc. |
| ◆ BioPharm International | ◆ HyClone Laboratories, Inc. | ◆ Neogen Corp. | ◆ TerraCell International |
| ◆ Bio-Rad Laboratories | ◆ Innovative Directions | ◆ Nova Biomedical | ◆ Wave Biotech |
| ◆ BioReliance Corp. | ◆ Irvine Scientific | ◆ Osmonics | ◆ YSI Inc. |
| ◆ Charles River Laboratories | ◆ J&J Scientific | ◆ Pall Life Sciences | |